Daru

Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease

By Andrea Matteucci, Stefania Angela Di Fusco, Michela Bonanni, Furio Colivicchi

ReviewInterventions

The paper

Andrea Matteucci, Stefania Angela Di Fusco, Michela Bonanni, Furio Colivicchi

Ospedale San Filippo Neri

Daru, 7 Aug 2026

doi.org/10.1007/s40199-026-00637-7 PubMed 42566081

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk